 |
|
|
| |
Investigating treatment strategies to optimise clinical outcomes associated with emerging therapies for HCV
|
| |
| |
Reported by Jules Levin
APASL, Asian Pacific Association for The Study of the Liver, 12 - 15 March 2014, Brisbane
Isao Kamae1, Thomas Ward2, Samantha Webster2, Masahiro Kobayashi3, Phil McEwan2,4, Anupama Kalsekar5,Yong Yuan5, Sachie Inoue6, Ann Tang7, Hiromitsu Kumada3
1Graduate School of Public Policy, The University of Tokyo, Japan; 2HEOR Ltd, Singleton Court Business Park, Monmouth, Wales, UK; 3Department of Hepatology, Toranomon Hospital, Japan; 4School of Human & Health Sciences, Swansea University, Wales, UK; 5Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ; 6CRECON Research and Consulting Inc., Japan; 7Health Economics and Outcomes Research, Bristol-Myers K.K., Japan
|
| |
|
|
|
|
|
